Landmarks for dual biological therapy in inflammatory bowel disease: Lesson from two case reports of vedolizumab in combination with ustekinumab

Giuseppe Biscaglia, Mariano Piazzolla, Francesco Cocomazzi, Gennaro Melchionda, Angelo De Cata, Fabrizio Bossa, Orazio Palmieri, Angelo Andriulli

Research output: Contribution to journalArticlepeer-review

Abstract

Inflammatory bowel disease (IBD) is a chronic and disabling disorder. Severity of IBD is prominent among refractory with patients with concomitant immune-mediated disorders. Among those patients, dual biological therapy (DBT) has been suggested as an alternative approach to spare steroids and avoid surgery. However, pieces of evidence on clinical outcomes among patients receiving DBT are still limited. We present two cases of IBD patients, with dermatological comorbidity, treated with a combination of vedolizumab and ustekinumab, identifying possible landmarks to address therapeutic choice. No patient experienced adverse events in the follow-up period and both obtained complete clinical remission. DBT may be an effective approach to consider in selected patients with refractory IBD with concomitant severe immune-mediated diseases taking into account medical history of the patient, presence, and type of concomitant extraintestinal manifestations, safety profile of selected DBT, licensed therapeutic indications, and costs.

Original languageEnglish
Pages (from-to)1579-1582
Number of pages4
JournalEuropean Journal of Gastroenterology and Hepatology
DOIs
Publication statusAccepted/In press - 2020

Keywords

  • dual biological therapy
  • extraintestinal manifestations
  • immune-mediated diseases
  • inflammatory bowel disease

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Landmarks for dual biological therapy in inflammatory bowel disease: Lesson from two case reports of vedolizumab in combination with ustekinumab'. Together they form a unique fingerprint.

Cite this